drugset / Trial / NCT01560507

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507

Phase 2/3 Terminated 19 enrolled Duke University Philip Morris USA · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to ascertain: 1) the rate of smoking cessation obtained using an adaptive treatment algorithm developed in previous clinical trials, in order to calculate cost-effectiveness of the treatment; 2) the relationship between genotype and response to cigarette smoking cessation treatment.

Timeline

Start
2012-05
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 150 mg
Comparator Nicotine Unknown 21 mg Other
Comparator Varenicline Small molecule 1 mg

Indications